{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:00:46Z","timestamp":1794373246094,"version":"4.9.0"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82300256"],"award-info":[{"award-number":["82300256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203317"],"award-info":[{"award-number":["82203317"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Young Doctor Talent Incubation Program of Xinqiao Hospital","award":["2022YQB016"],"award-info":[{"award-number":["2022YQB016"]}]},{"name":"Young Doctor Talent Incubation Program of Xinqiao Hospital","award":["2023YQB010"],"award-info":[{"award-number":["2023YQB010"]}]},{"name":"Chongqing Technology Innovation and Application Development Key Projects","award":["CSTB2022TIAD-CUX0019"],"award-info":[{"award-number":["CSTB2022TIAD-CUX0019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Lung cancer is a major malignant tumor with high morbidity and fatality rates. For many years, traditional treatments for lung cancer have struggled to achieve a favorable outlook and prognosis. It is crucial to identify and innovate novel clinical therapeutic strategies and techniques to prevent tumor progression and prolong the survival time of patients with lung cancer. Cellular immunotherapies have revolutionized the treatment of malignant tumors and have been gradually applied in clinical practice. CAR-T therapy is the best-known cellular therapy and has achieved remarkable clinical outcomes in patients with hematological malignancies, but its effect on patients with lung cancer and other solid tumors is not satisfactory, partly because of the heterogeneity and complexity of lung cancers and the sterile TMEs. To further improve the clinical effect, multiple approaches and strategies have been adopted, including discovering new tumor antigen targets, improving safety, enhancing cytotoxicity, and increasing durability. Moreover, other cell-based immunotherapies have also showed great potential for the treatment of lung cancer, including TCR-T cells, TILs, CIK cells, NK cells, macrophages, and dendritic cells, which enriched the number of treatment choices for patients with lung cancer. In summary, the present article summarizes and highlights recent advances and challenges in the use of cellular immunotherapies for the treatment of lung cancer, which might stimulate new ideas for the further development of cellular immunotherapies.<\/jats:p>","DOI":"10.1186\/s40164-025-00679-8","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:19:07Z","timestamp":1751894347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent advances and challenges of cellular immunotherapies in lung cancer treatment"],"prefix":"10.1186","volume":"14","author":[{"given":"Chengfei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"10299","key":"679_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"9","key":"679_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"679_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"679_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"679_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamaoncol.2023.5276","volume":"10","author":"HJ West","year":"2024","unstructured":"West HJ, Kim JY. Rapid advances in resectable Non-Small cell lung cancer: A narrative review. JAMA Oncol. 2024;10(2):249\u201355.","journal-title":"JAMA Oncol"},{"issue":"10","key":"679_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx A, Chan JKC, Coindre J-M, Detterbeck F, Girard N, Harris NL, et al. The 2015 world health organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383\u201395.","journal-title":"J Thorac Oncol"},{"issue":"10066","key":"679_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299\u2013311.","journal-title":"Lancet"},{"issue":"10","key":"679_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"679_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.12916","volume":"10","author":"M Cao","year":"2019","unstructured":"Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3\u20137.","journal-title":"Thorac Cancer"},{"issue":"10125","key":"679_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"1","key":"679_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78\u201384.","journal-title":"Lung Cancer"},{"issue":"1","key":"679_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40.","journal-title":"Mol Cancer"},{"issue":"6","key":"679_CR13","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1007\/s13346-021-00923-8","volume":"11","author":"A Ukidve","year":"2021","unstructured":"Ukidve A, Cu K, Kumbhojkar N, Lahann J, Mitragotri S. Overcoming biological barriers to improve solid tumor immunotherapy. Drug Deliv Transl Res. 2021;11(6):2276\u2013301.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"679_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"679_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320.","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"679_CR16","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-23-1159","volume":"30","author":"J Zugazagoitia","year":"2024","unstructured":"Zugazagoitia J, Osma H, Baena J, Ucero AC, Paz-Ares L. Facts and hopes on Cancer immunotherapy for small cell lung Cancer. Clin Cancer Res. 2024;30(14):2872\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"679_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual Blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17(1):54.","journal-title":"J Hematol Oncol"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"799455","DOI":"10.3389\/fimmu.2021.799455","volume":"12","author":"C Genova","year":"2021","unstructured":"Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint Blockade. Front Immunol. 2021;12:799455.","journal-title":"Front Immunol"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.critrevonc.2019.08.009","volume":"143","author":"T Abu Hejleh","year":"2019","unstructured":"Abu Hejleh T, Furqan M, Ballas Z, Clamon G. The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit Rev Oncol Hematol. 2019;143:148\u201352.","journal-title":"Crit Rev Oncol Hematol"},{"key":"679_CR20","doi-asserted-by":"crossref","unstructured":"Sui H, Ma N, Wang Y, Li H, Liu X, Su Y et al. Anti-PD-1\/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. J Immunol Res. 2018; 2018:6984948.","DOI":"10.1155\/2018\/6984948"},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"830631","DOI":"10.3389\/fimmu.2022.830631","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin J, Wu Y, Yang X, Gan L, Xue J. Checkpoint inhibitor pneumonitis induced by Anti-PD-1\/PD-L1 therapy in Non-Small-Cell lung cancer: occurrence and mechanism. Front Immunol. 2022;13:830631.","journal-title":"Front Immunol"},{"issue":"21","key":"679_CR22","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic Non-Small-Cell lung Cancer with PD-L1 tumor proportion score\u2009\u2265\u200950. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"6","key":"679_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, et al. Perioperative pembrolizumab for Early-Stage Non-Small-Cell lung Cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"153303382412496","DOI":"10.1177\/15330338241249690","volume":"23","author":"C Chen","year":"2024","unstructured":"Chen C, Chen M, Bai Y, Li Y, Peng J, Yao B, et al. A Single-Arm Multi-Center phase II clinical trial of cadonilimab (anti-PD-1\/CTLA-4) in combination with or without conventional Second-Line treatment for patients with extensive stage small cell lung Cancer. Technol Cancer Res Treat. 2024;23:15330338241249690.","journal-title":"Technol Cancer Res Treat"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, et al. A multicenter, open-label phase ib\/ii study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023;184:107355.","journal-title":"Lung Cancer"},{"issue":"11","key":"679_CR26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(24)00218-2","volume":"12","author":"MSC Li","year":"2024","unstructured":"Li MSC, Saw SPL, Addeo A. Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study. Lancet Respir Med. 2024;12(11):840\u20132.","journal-title":"Lancet Respir Med"},{"issue":"6382","key":"679_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"1","key":"679_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"M-Y Xu","year":"2024","unstructured":"Xu M-Y, Zeng N, Liu C-Q, Sun J-X, An Y, Zhang S-H, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47.","journal-title":"Exp Hematol Oncol"},{"issue":"24","key":"679_CR29","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"679_CR30","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"19","key":"679_CR31","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875\u201386.","journal-title":"Blood"},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang Y-J, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"12","key":"679_CR33","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33(12):2767\u201378.","journal-title":"Leukemia"},{"issue":"3","key":"679_CR34","first-page":"166","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(3):166.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"679_CR35","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-Generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625\u201333.","journal-title":"Cancer Discov"},{"issue":"1","key":"679_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139\u201352.","journal-title":"Annu Rev Med"},{"issue":"11","key":"679_CR38","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality?? Mol Ther. 2020;28(11):2320\u201339.","journal-title":"Mol Ther"},{"key":"679_CR39","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.","journal-title":"EBioMedicine"},{"issue":"6","key":"679_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"key":"679_CR41","doi-asserted-by":"crossref","unstructured":"Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021; 9(10).","DOI":"10.1136\/jitc-2021-003354"},{"issue":"1","key":"679_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"J Tan","year":"2022","unstructured":"Tan J, Jia Y, Zhou M, Fu C, Tuhin IJ, Ye J, et al. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J Hematol Oncol. 2022;15(1):39.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"679_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C-H, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"679_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","volume":"30","author":"A Hombach","year":"2022","unstructured":"Hombach A, Barden M, Hannappel L, Chmielewski M, Rappl G, Sachinidis A, et al. IL12 integrated into the CAR exodomain converts CD8\u2009+\u2009T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol Ther. 2022;30(2):593\u2013605.","journal-title":"Mol Ther"},{"issue":"3","key":"679_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, et al. Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309\u201320.","journal-title":"Cancer Immunol Res"},{"key":"679_CR46","doi-asserted-by":"crossref","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023; 133(9).","DOI":"10.1172\/JCI166028"},{"key":"679_CR47","doi-asserted-by":"crossref","unstructured":"Noh K-E, Lee J-H, Choi S-Y, Jung N-C, Nam J-H, Oh J-S et al. TGF-\u03b2\/IL-7 chimeric switch Receptor-Expressing CAR-T cells inhibit recurrence of CD19-Positive B cell lymphoma. Int J Mol Sci. 2021; 22(16).","DOI":"10.3390\/ijms22168706"},{"issue":"4","key":"679_CR48","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41416-023-02332-9","volume":"129","author":"T Lorenzini","year":"2023","unstructured":"Lorenzini T, Cadilha BL, Obeck H, Benmebarek M-R, M\u00e4rkl F, Michaelides S, et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer. 2023;129(4):696\u2013705.","journal-title":"Br J Cancer"},{"issue":"1","key":"679_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","volume":"14","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P, et al. CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021;14(1):26.","journal-title":"J Hematol Oncol"},{"key":"679_CR50","doi-asserted-by":"publisher","first-page":"642528","DOI":"10.3389\/fimmu.2021.642528","volume":"12","author":"S Lin","year":"2021","unstructured":"Lin S, Cheng L, Ye W, Li S, Zheng D, Qin L, et al. Chimeric CTLA4-CD28-CD3z T cells potentiate antitumor activity against CD80\/CD86-Positive B cell malignancies. Front Immunol. 2021;12:642528.","journal-title":"Front Immunol"},{"issue":"1","key":"679_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.intimp.2013.11.009","volume":"18","author":"A Noguchi","year":"2014","unstructured":"Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. Int Immunopharmacol. 2014;18(1):90\u20137.","journal-title":"Int Immunopharmacol"},{"key":"679_CR52","doi-asserted-by":"crossref","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access?? Cells. 2018; 7(10).","DOI":"10.3390\/cells7100155"},{"issue":"S1","key":"679_CR53","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1002\/ajh.25399","volume":"94","author":"W Qasim","year":"2019","unstructured":"Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019;94(S1):S50\u20134.","journal-title":"Am J Hematol"},{"issue":"4","key":"679_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","volume":"18","author":"AM DiNofia","year":"2021","unstructured":"DiNofia AM, Grupp SA. Will allogeneic CAR T cells for CD19\u2009+\u2009malignancies take autologous CAR T cells \u2018off the shelf\u2019? Nat Rev Clin Oncol. 2021;18(4):195\u20136.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10266","key":"679_CR55","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885\u201394.","journal-title":"Lancet"},{"issue":"6","key":"679_CR56","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang X-Q, Zhang R-L, Liu F, Wang Y, Yan Z-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563\u201370.","journal-title":"Leukemia"},{"issue":"14","key":"679_CR57","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","volume":"82","author":"SH Panowski","year":"2022","unstructured":"Panowski SH, Srinivasan S, Tan N, Tacheva-Grigorova SK, Smith B, Mak YSL, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. Cancer Res. 2022;82(14):2610\u201324.","journal-title":"Cancer Res"},{"issue":"5","key":"679_CR58","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-22-2293","volume":"29","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Tacheva-Grigorova SK, Sutton J, Melton Z, Mak YSL, Lay C, et al. Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung Cancer. Clin Cancer Res. 2023;29(5):971\u201385.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"679_CR59","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","volume":"23","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23(14):3227\u201334.","journal-title":"J Clin Oncol"},{"issue":"15","key":"679_CR60","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1158\/1078-0432.CCR-08-2921","volume":"15","author":"M Sun","year":"2009","unstructured":"Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009;15(15):4829\u201337.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"679_CR61","doi-asserted-by":"publisher","first-page":"50209","DOI":"10.18632\/oncotarget.16854","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017;8(30):50209\u201320.","journal-title":"Oncotarget"},{"issue":"6","key":"679_CR62","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2024.0584","volume":"10","author":"V Noronha","year":"2024","unstructured":"Noronha V, Patil V, Menon N, Shah M, Chougule A, Peelay Z, et al. Gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-Variant lung Cancer-Long-Term results of a randomized clinical trial. JAMA Oncol. 2024;10(6):824\u20136.","journal-title":"JAMA Oncol"},{"issue":"1","key":"679_CR63","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1186\/s12885-019-6107-1","volume":"19","author":"G-F Ho","year":"2019","unstructured":"Ho G-F, Chai C-S, Alip A, Wahid MIA, Abdullah MM, Foo Y-C, et al. Real-world experience of first-line Afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19(1):896.","journal-title":"BMC Cancer"},{"issue":"1","key":"679_CR64","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(19)30778-8","volume":"21","author":"E Gourd","year":"2020","unstructured":"Gourd E. Overall survival with osimertinib in untreated NSCLC. Lancet Oncol. 2020;21(1):e15.","journal-title":"Lancet Oncol"},{"issue":"5","key":"679_CR65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468\u201379.","journal-title":"Sci China Life Sci"},{"issue":"12","key":"679_CR66","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggybac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"key":"679_CR67","doi-asserted-by":"crossref","unstructured":"Wang J, Wang Y, Pan H, Zhao L, Yang X, Liang Z et al. Chemokine receptors CCR6 and PD1 blocking ScFv E27 enhances Anti-EGFR CAR-T therapeutic efficacy in a preclinical model of human Non-Small cell lung carcinoma. Int J Mol Sci. 2023; 24(6).","DOI":"10.3390\/ijms24065424"},{"issue":"9","key":"679_CR68","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/resp.14541","volume":"28","author":"G Li","year":"2023","unstructured":"Li G, Liao G, Xie J, Liu B, Li X, Qiu M. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer. Respirology. 2023;28(9):869\u201380.","journal-title":"Respirology"},{"issue":"3\u20134","key":"679_CR69","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u201371.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"679_CR70","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138\u201343.","journal-title":"Lung Cancer"},{"key":"679_CR71","doi-asserted-by":"crossref","unstructured":"Kumar J, Kumar R, Kumar Singh A, Tsakem EL, Kathania M, Riese MJ et al. Deletion of Cbl-b inhibits CD8\u2009+\u2009T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 2021; 9(1).","DOI":"10.1136\/jitc-2020-001688"},{"key":"679_CR72","doi-asserted-by":"publisher","first-page":"1182409","DOI":"10.3389\/fimmu.2023.1182409","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang L, Zhang Q, Shen J, Huang X, Wang M, et al. Screening and characterization of the ScFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma. Front Immunol. 2023;14:1182409.","journal-title":"Front Immunol"},{"issue":"11","key":"679_CR73","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","volume":"27","author":"NG Ord\u00f3\u00f1ez","year":"2003","unstructured":"Ord\u00f3\u00f1ez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418\u201328.","journal-title":"Am J Surg Pathol"},{"key":"679_CR74","doi-asserted-by":"crossref","unstructured":"Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM et al. Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors. Biomedicines. 2021; 9(4).","DOI":"10.3390\/biomedicines9040397"},{"issue":"34","key":"679_CR75","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time?? J Clin Oncol. 2016;34(34):4171\u20139.","journal-title":"J Clin Oncol"},{"key":"679_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.003","volume":"165","author":"M Ghosn","year":"2022","unstructured":"Ghosn M, Cheema W, Zhu A, Livschitz J, Maybody M, Boas FE, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial. Lung Cancer. 2022;165:1\u20139.","journal-title":"Lung Cancer"},{"key":"679_CR77","doi-asserted-by":"crossref","unstructured":"Tokatlian T, Asuelime GE, Mock J-Y, DiAndreth B, Sharma S, Toledo Warshaviak D et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer. 2022; 10(1).","DOI":"10.1136\/jitc-2021-003826"},{"key":"679_CR78","doi-asserted-by":"publisher","first-page":"628906","DOI":"10.3389\/fimmu.2021.628906","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, et al. Chemokine receptor CCR2b enhanced Anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a Non-small-cell lung carcinoma model. Front Immunol. 2021;12:628906.","journal-title":"Front Immunol"},{"key":"679_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski","year":"2014","unstructured":"Roskoski R. The erbb\/her family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34\u201374.","journal-title":"Pharmacol Res"},{"issue":"1","key":"679_CR80","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157\u201364.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"679_CR81","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1586\/14737140.2013.846830","volume":"13","author":"L Landi","year":"2013","unstructured":"Landi L, Cappuzzo F. HER2 and lung cancer. Expert Rev Anticancer Ther. 2013;13(10):1219\u201328.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"679_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16.","journal-title":"Biomark Res"},{"key":"679_CR83","doi-asserted-by":"crossref","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK et al. Regional delivery of chimeric antigen Receptor-Engineered T cells effectively targets HER2\u2009+\u2009Breast Cancer metastasis to the brain. Clin Cancer Res. 2018; 24(1).","DOI":"10.1158\/1078-0432.CCR-17-2041"},{"issue":"10","key":"679_CR84","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","volume":"9","author":"Y Song","year":"2018","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867\u201378.","journal-title":"Protein Cell"},{"issue":"15","key":"679_CR85","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -Specific chimeric antigen receptor-Modified T cells for the immunotherapy of HER2-Positive sarcoma. J Clin Oncol. 2015;33(15):1688\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"679_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted CXCL11 promoted CD8\u2009+\u2009T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019;7(1):42.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"679_CR87","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1158\/2326-6066.CIR-21-0652","volume":"10","author":"Q Gao","year":"2022","unstructured":"Gao Q, Wang S, Li F, Lian J, Cheng S, Yue D, et al. High mobility group protein B1 decreases surface localization of PD-1 to augment T-cell activation. Cancer Immunol Res. 2022;10(7):844\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"679_CR88","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140(14):1583\u201391.","journal-title":"Blood"},{"key":"679_CR89","doi-asserted-by":"crossref","unstructured":"Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J et al. Phase I trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018; 22(6).","DOI":"10.1016\/j.stem.2018.05.018"},{"issue":"5","key":"679_CR90","doi-asserted-by":"publisher","first-page":"e22726","DOI":"10.1002\/jbt.22726","volume":"35","author":"F Li","year":"2021","unstructured":"Li F, Gu F, Li Q, Zhai C, Gong R, Zhu X. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K\/Akt\/mTOR pathway. J Biochem Mol Toxicol. 2021;35(5):e22726.","journal-title":"J Biochem Mol Toxicol"},{"key":"679_CR91","doi-asserted-by":"crossref","unstructured":"Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint Blockade. Cancer Cell. 2021; 39(2).","DOI":"10.1016\/j.ccell.2020.11.005"},{"issue":"1","key":"679_CR92","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1038\/s41598-022-10905-6","volume":"12","author":"Z Ou","year":"2022","unstructured":"Ou Z, Dou X, Tang N, Liu G. Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity. Sci Rep. 2022;12(1):6919.","journal-title":"Sci Rep"},{"issue":"1","key":"679_CR93","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/COC.0b013e31828f5a07","volume":"38","author":"K Pillai","year":"2015","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL. MUC1 as a potential target in anticancer therapies. Am J Clin Oncol. 2015;38(1):108\u201318.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"679_CR94","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/glycob\/cwj110","volume":"16","author":"S Parry","year":"2006","unstructured":"Parry S, Hanisch FG, Leir S-H, Sutton-Smith M, Morris HR, Dell A, et al. N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology. 2006;16(7):623\u201334.","journal-title":"Glycobiology"},{"key":"679_CR95","doi-asserted-by":"crossref","unstructured":"Sun L, Zhang Y, Li W, Zhang J, Zhang Y. Mucin glycans: A target for Cancer therapy. Molecules. 2023; 28(20).","DOI":"10.3390\/molecules28207033"},{"issue":"9","key":"679_CR96","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/glycob\/cwy008","volume":"28","author":"C Steentoft","year":"2018","unstructured":"Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD. Glycan-directed CAR-T cells. Glycobiology. 2018;28(9):656\u201369.","journal-title":"Glycobiology"},{"key":"679_CR97","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.cellimm.2023.104760","volume":"391\u2013392","author":"A Wang","year":"2023","unstructured":"Wang A, Lv T, Song Y. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. Cell Immunol. 2023;391\u2013392:104760.","journal-title":"Cell Immunol"},{"issue":"2","key":"679_CR98","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2008.08.034","volume":"277","author":"AB Raff","year":"2009","unstructured":"Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009;277(2):126\u201332.","journal-title":"Cancer Lett"},{"issue":"4","key":"679_CR99","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","volume":"95","author":"RE Reiter","year":"1998","unstructured":"Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95(4):1735\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"679_CR100","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jjco\/hyp181","volume":"40","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi T, Sho M, Tojo T, Yamato I, Nomi T, Hotta K, et al. Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol. 2010;40(4):319\u201326.","journal-title":"Jpn J Clin Oncol"},{"key":"679_CR101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-020-0183-x","volume":"8","author":"D Wu","year":"2020","unstructured":"Wu D, Lv J, Zhao R, Wu Z, Zheng D, Shi J, et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res. 2020;8:3.","journal-title":"Biomark Res"},{"issue":"3","key":"679_CR102","doi-asserted-by":"publisher","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.","journal-title":"Oncoimmunology"},{"issue":"1","key":"679_CR103","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 Blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"679_CR104","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"issue":"12","key":"679_CR105","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/annonc\/mdv394","volume":"26","author":"G Middleton","year":"2015","unstructured":"Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, et al. The National lung matrix trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol. 2015;26(12):2464\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"679_CR106","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","volume":"9","author":"M Liu","year":"2020","unstructured":"Liu M, Wang X, Li W, Yu X, Flores-Villanueva P, Xu-Monette ZY, et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020;9(8):72.","journal-title":"Oncogenesis"},{"key":"679_CR107","doi-asserted-by":"crossref","unstructured":"Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022; 10(1).","DOI":"10.1136\/jitc-2021-002500"},{"issue":"1","key":"679_CR108","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","volume":"14","author":"H-J Liu","year":"2023","unstructured":"Liu H-J, Du H, Khabibullin D, Zarei M, Wei K, Freeman GJ, et al. mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun. 2023;14(1):1214.","journal-title":"Nat Commun"},{"issue":"5","key":"679_CR109","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"679_CR110","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/cr.2017.90","volume":"27","author":"Y-H Lee","year":"2017","unstructured":"Lee Y-H, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034\u201345.","journal-title":"Cell Res"},{"issue":"10","key":"679_CR111","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","volume":"27","author":"NM Kendsersky","year":"2021","unstructured":"Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, et al. The B7-H3-Targeting Antibody-Drug conjugate m276-SL-PBD is potently effective against pediatric Cancer preclinical solid tumor models. Clin Cancer Res. 2021;27(10):2938\u201346.","journal-title":"Clin Cancer Res"},{"key":"679_CR112","doi-asserted-by":"crossref","unstructured":"Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B et al. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers (Basel). 2020; 12(9).","DOI":"10.3390\/cancers12092659"},{"key":"679_CR113","doi-asserted-by":"crossref","unstructured":"Belluomini L, Sposito M, Avancini A, Insolda J, Milella M, Rossi A et al. Unlocking new horizons in Small-Cell lung Cancer treatment: the onset of Antibody-Drug conjugates. Cancers (Basel). 2023; 15(22).","DOI":"10.3390\/cancers15225368"},{"issue":"17","key":"679_CR114","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"issue":"1","key":"679_CR115","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Harrison EB, Li H, Hirabayashi K, Chen J, Li Q-X, et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022;13(1):2154.","journal-title":"Nat Commun"},{"issue":"43","key":"679_CR116","doi-asserted-by":"publisher","first-page":"e2102624","DOI":"10.1002\/smll.202102624","volume":"17","author":"L Zhu","year":"2021","unstructured":"Zhu L, Liu J, Zhou G, Liu T-M, Dai Y, Nie G, et al. Remodeling of tumor microenvironment by tumor-Targeting nanozymes enhances immune activation of CAR T cells for combination therapy. Small. 2021;17(43):e2102624.","journal-title":"Small"},{"key":"679_CR117","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"147","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D, \u00d6z AB, Biesma B, Brcic L, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237\u201343.","journal-title":"Lung Cancer"},{"issue":"5","key":"679_CR118","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/cas.13997","volume":"110","author":"M Furuta","year":"2019","unstructured":"Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, et al. DLL3 regulates the migration and invasion of small cell lung cancer by modulating snail. Cancer Sci. 2019;110(5):1599\u2013608.","journal-title":"Cancer Sci"},{"key":"679_CR119","doi-asserted-by":"crossref","unstructured":"Dolkar T, Gates C, Hao Z, Munker R. New developments in immunotherapy for SCLC. J Immunother Cancer. 2025; 13(1).","DOI":"10.1136\/jitc-2024-009667"},{"issue":"4","key":"679_CR120","doi-asserted-by":"publisher","first-page":"956","DOI":"10.21037\/tlcr-24-10","volume":"13","author":"E Noguera-Ortega","year":"2024","unstructured":"Noguera-Ortega E, Albelda SM. Small cell, big promises: targeting small cell lung cancer with CAR T cells. Transl Lung Cancer Res. 2024;13(4):956\u201360.","journal-title":"Transl Lung Cancer Res"},{"key":"679_CR121","doi-asserted-by":"crossref","unstructured":"Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fuc\u00e0 G et al. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 2022; 10(1).","DOI":"10.1136\/jitc-2021-003897"},{"issue":"1","key":"679_CR122","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tranon.2017.10.009","volume":"11","author":"N Li","year":"2018","unstructured":"Li N, Liu S, Sun M, Chen W, Xu X, Zeng Z, et al. Chimeric antigen Receptor-Modified T cells redirected to EphA2 for the immunotherapy of Non-Small cell lung Cancer. Transl Oncol. 2018;11(1):11\u20137.","journal-title":"Transl Oncol"},{"issue":"1","key":"679_CR123","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-019-0793-7","volume":"12","author":"Y Mao","year":"2019","unstructured":"Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, et al. MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol. 2019;12(1):106.","journal-title":"J Hematol Oncol"},{"key":"679_CR124","doi-asserted-by":"publisher","first-page":"665970","DOI":"10.3389\/fimmu.2021.665970","volume":"12","author":"Y Jie","year":"2021","unstructured":"Jie Y, Liu G, Feng L, Li Y, E M, Wu L, et al. PTK7-Targeting CAR T-Cells for the treatment of lung Cancer and other malignancies. Front Immunol. 2021;12:665970.","journal-title":"Front Immunol"},{"issue":"7","key":"679_CR125","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current Understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"S1","key":"679_CR126","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/ajh.25445","volume":"94","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019;94(S1):S42\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"679_CR127","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"key":"679_CR128","doi-asserted-by":"crossref","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019; 11(499).","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"679_CR129","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"issue":"3","key":"679_CR130","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible Caspase-9 selectively modulates the toxicities of CD19-Specific chimeric antigen Receptor-Modified T cells. Mol Ther. 2017;25(3):580\u201392.","journal-title":"Mol Ther"},{"key":"679_CR131","doi-asserted-by":"crossref","unstructured":"Yang L, Yin J, Wu J, Qiao L, Zhao EM, Cai F et al. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. Proc Natl Acad Sci U S A. 2021; 118(34).","DOI":"10.1073\/pnas.2106612118"},{"key":"679_CR132","doi-asserted-by":"crossref","unstructured":"Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022; 185(10).","DOI":"10.1016\/j.cell.2022.03.041"},{"issue":"1","key":"679_CR133","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-024-01648-0","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q, et al. Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. J Hematol Oncol. 2024;17(1):122.","journal-title":"J Hematol Oncol"},{"key":"679_CR134","doi-asserted-by":"publisher","first-page":"724211","DOI":"10.3389\/fimmu.2021.724211","volume":"12","author":"A Zhang","year":"2021","unstructured":"Zhang A, Sun Y, Du J, Dong Y, Pang H, Ma L, et al. Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release. Front Immunol. 2021;12:724211.","journal-title":"Front Immunol"},{"issue":"11","key":"679_CR135","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, et al. Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"issue":"6","key":"679_CR136","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353.","journal-title":"Nat Med"},{"key":"679_CR137","doi-asserted-by":"crossref","unstructured":"Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J Immunother Cancer. 2023; 11(2).","DOI":"10.1136\/jitc-2022-005701"},{"issue":"1","key":"679_CR138","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Sharma A, Schmidt-Wolf IGH. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 Blockade in the clinical spectrum of lung cancer. Mol Cancer. 2024;23(1):80.","journal-title":"Mol Cancer"},{"issue":"10","key":"679_CR139","doi-asserted-by":"publisher","first-page":"e2200626120","DOI":"10.1073\/pnas.2200626120","volume":"120","author":"S D\u00f6tsch","year":"2023","unstructured":"D\u00f6tsch S, Svec M, Schober K, Hammel M, Wanisch A, G\u00f6kmen F, et al. Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. Proc Natl Acad Sci U S A. 2023;120(10):e2200626120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"679_CR140","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.","journal-title":"Sci Rep"},{"key":"679_CR141","doi-asserted-by":"publisher","first-page":"102010","DOI":"10.1016\/j.eclinm.2023.102010","volume":"60","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zu C, Zhang M, Wei G, Li W, Fu S, et al. Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study. EClinicalMedicine. 2023;60:102010.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"679_CR142","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking ScFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"679_CR143","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","volume":"43","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chen J, Wang X, Yan S, Tan J, Xia B, et al. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Commun (Lond). 2023;43(7):788\u2013807.","journal-title":"Cancer Commun (Lond)"},{"key":"679_CR144","doi-asserted-by":"crossref","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023; 56(10).","DOI":"10.1016\/j.immuni.2023.09.001"},{"issue":"1","key":"679_CR145","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41467-019-11893-4","volume":"10","author":"F Zou","year":"2019","unstructured":"Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, et al. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun. 2019;10(1):4109.","journal-title":"Nat Commun"},{"issue":"1","key":"679_CR146","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40164-023-00450-x","volume":"12","author":"M Liu","year":"2023","unstructured":"Liu M, Zhang L, Zhong M, Long Y, Yang W, Liu T, et al. CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro. Exp Hematol Oncol. 2023;12(1):88.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"679_CR147","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","volume":"12","author":"F Wiede","year":"2022","unstructured":"Wiede F, Lu K-H, Du X, Zeissig MN, Xu R, Goh PK, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 2022;12(3):752\u201373.","journal-title":"Cancer Discov"},{"issue":"4","key":"679_CR148","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint Blockade-Based combination therapies. Cancer Cell. 2018;33(4):581\u201398.","journal-title":"Cancer Cell"},{"issue":"12","key":"679_CR149","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. Cish actively silences TCR signaling in CD8\u2009+\u2009T cells to maintain tumor tolerance. J Exp Med. 2015;212(12):2095\u2013113.","journal-title":"J Exp Med"},{"key":"679_CR150","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","volume":"28","author":"J Lv","year":"2023","unstructured":"Lv J, Qin L, Zhao R, Wu D, Wu Z, Zheng D, et al. Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Mol Ther Oncolytics. 2023;28:46\u201358.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"679_CR151","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12(1):3236.","journal-title":"Nat Commun"},{"issue":"3","key":"679_CR152","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(3):929\u201341.","journal-title":"J Clin Invest"},{"key":"679_CR153","doi-asserted-by":"crossref","unstructured":"Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8\u2009+\u2009T cells in glioma patients. Neuro Oncol. 2010; 12(1).","DOI":"10.1093\/neuonc\/nop009"},{"key":"679_CR154","doi-asserted-by":"crossref","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W et al. TGF-\u03b2 Inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020; 5(4).","DOI":"10.1172\/jci.insight.133977"},{"issue":"2","key":"679_CR155","doi-asserted-by":"publisher","first-page":"101400","DOI":"10.1016\/j.xcrm.2024.101400","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5(2):101400.","journal-title":"Cell Rep Med"},{"key":"679_CR156","doi-asserted-by":"publisher","first-page":"113395","DOI":"10.1016\/j.biopha.2022.113395","volume":"153","author":"W Li","year":"2022","unstructured":"Li W, Liang L, Liao Q, Li Y, Zhou Y. CD38: an important regulator of T cell function. Biomed Pharmacother. 2022;153:113395.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"679_CR157","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.","journal-title":"Biomark Res"},{"issue":"1","key":"679_CR158","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri3567","volume":"14","author":"DL Farber","year":"2014","unstructured":"Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24\u201335.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"679_CR159","first-page":"594","volume":"123","author":"E Lugli","year":"2013","unstructured":"Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594\u20139.","journal-title":"J Clin Invest"},{"issue":"1","key":"679_CR160","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. 2017;23(1):18\u201327.","journal-title":"Nat Med"},{"issue":"1","key":"679_CR161","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nprot.2012.143","volume":"8","author":"E Lugli","year":"2013","unstructured":"Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc. 2013;8(1):33\u201342.","journal-title":"Nat Protoc"},{"issue":"4","key":"679_CR162","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, et al. Generation of clinical-grade CD19-specific CAR-modified CD8\u2009+\u2009memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128(4):519\u201328.","journal-title":"Blood"},{"key":"679_CR163","doi-asserted-by":"publisher","first-page":"877682","DOI":"10.3389\/fimmu.2022.877682","volume":"13","author":"E Kranz","year":"2022","unstructured":"Kranz E, Kuhlmann CJ, Chan J, Kim PY, Chen ISY, Kamata M. Efficient derivation of chimeric-antigen receptor-modified TSCM cells. Front Immunol. 2022;13:877682.","journal-title":"Front Immunol"},{"issue":"24","key":"679_CR164","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u201390.","journal-title":"Blood"},{"issue":"9","key":"679_CR165","first-page":"CD013365","volume":"9","author":"M Ernst","year":"2021","unstructured":"Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021;9(9):CD013365.","journal-title":"Cochrane Database Syst Rev"},{"issue":"625","key":"679_CR166","doi-asserted-by":"publisher","first-page":"eabg7565","DOI":"10.1126\/scitranslmed.abg7565","volume":"13","author":"P-J Aspuria","year":"2021","unstructured":"Aspuria P-J, Vivona S, Bauer M, Semana M, Ratti N, McCauley S, et al. An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci Transl Med. 2021;13(625):eabg7565.","journal-title":"Sci Transl Med"},{"issue":"1","key":"679_CR167","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling cars: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"679_CR168","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12967-021-03165-x","volume":"19","author":"M Zhang","year":"2021","unstructured":"Zhang M, Jin X, Sun R, Xiong X, Wang J, Xie D, et al. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med. 2021;19(1):499.","journal-title":"J Transl Med"},{"issue":"6614","key":"679_CR169","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1126\/science.ade3697","volume":"377","author":"JA Nathan","year":"2022","unstructured":"Nathan JA. Metabolite-driven antitumor immunity. Science. 2022;377(6614):1488\u20139.","journal-title":"Science"},{"issue":"24","key":"679_CR170","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20139.","journal-title":"Blood"},{"issue":"11","key":"679_CR171","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","volume":"28","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida L, Sek K, Henderson MA, House IG, Lai J, Chen AXY, et al. IL-15 preconditioning augments CAR T cell responses to checkpoint Blockade for improved treatment of solid tumors. Mol Ther. 2020;28(11):2379\u201393.","journal-title":"Mol Ther"},{"key":"679_CR172","doi-asserted-by":"crossref","unstructured":"Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer. 2021; 9(1).","DOI":"10.1136\/jitc-2020-001647"},{"issue":"11","key":"679_CR173","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"679_CR174","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, et al. Microbial short-chain fatty acids modulate CD8\u2009+\u2009T cell responses and improve adoptive immunotherapy for cancer. Nat Commun. 2021;12(1):4077.","journal-title":"Nat Commun"},{"issue":"7","key":"679_CR175","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41375-024-02257-z","volume":"38","author":"G Gross","year":"2024","unstructured":"Gross G, Alkadieri S, Meir A, Itzhaki O, Aharoni-Tevet Y, Ben Yosef S, et al. Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose. Leukemia. 2024;38(7):1534\u201340.","journal-title":"Leukemia"},{"issue":"6468","key":"679_CR176","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun I-M, Oh M-H, Sun I-H, et al. Glutamine Blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013\u201321.","journal-title":"Science"},{"key":"679_CR177","doi-asserted-by":"crossref","unstructured":"Pilipow K, Scamardella E, Puccio S, Gautam S, De Paoli F, Mazza EM et al. Antioxidant metabolism regulates CD8\u2009+\u2009T memory stem cell formation and antitumor immunity. JCI Insight. 2018; 3(18).","DOI":"10.1172\/jci.insight.122299"},{"issue":"4","key":"679_CR178","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","volume":"139","author":"CR Funk","year":"2022","unstructured":"Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, et al. PI3K\u03b4\/\u03b3 Inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523\u201337.","journal-title":"Blood"},{"issue":"5","key":"679_CR179","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ijc.32201","volume":"145","author":"S Stock","year":"2019","unstructured":"Stock S, \u00dcbelhart R, Schubert M-L, Fan F, He B, Hoffmann J-M, et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int J Cancer. 2019;145(5):1312\u201324.","journal-title":"Int J Cancer"},{"issue":"88","key":"679_CR180","doi-asserted-by":"publisher","first-page":"35807","DOI":"10.18632\/oncotarget.26334","volume":"9","author":"W Zheng","year":"2018","unstructured":"Zheng W, Jones LL, Geiger TL. Modulation of PI3K signaling to improve CAR T cell function. Oncotarget. 2018;9(88):35807\u20138.","journal-title":"Oncotarget"},{"key":"679_CR181","doi-asserted-by":"crossref","unstructured":"Appelbaum J, Price AE, Oda K, Zhang J, Leung W-H, Tampella G et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized Rapamycin dosing. J Clin Invest. 2024; 134(9).","DOI":"10.1172\/JCI162593"},{"issue":"7709","key":"679_CR182","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307\u201312.","journal-title":"Nature"},{"issue":"1","key":"679_CR183","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409.","journal-title":"Nat Commun"},{"issue":"4","key":"679_CR184","doi-asserted-by":"publisher","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"M Zhu","year":"2024","unstructured":"Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43(4):114065.","journal-title":"Cell Rep"},{"issue":"9","key":"679_CR185","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.4049\/jimmunol.1901213","volume":"204","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin enhances the antitumor activity of CD8\u2009+\u2009T lymphocytes via the AMPK-miR-107-Eomes-PD-1 pathway. J Immunol. 2020;204(9):2575\u201388.","journal-title":"J Immunol"},{"key":"679_CR186","doi-asserted-by":"publisher","first-page":"122052","DOI":"10.1016\/j.biomaterials.2023.122052","volume":"295","author":"Y Chao","year":"2023","unstructured":"Chao Y, Wei T, Li Q, Liu B, Hao Y, Chen M, et al. Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors. Biomaterials. 2023;295:122052.","journal-title":"Biomaterials"},{"key":"679_CR187","doi-asserted-by":"crossref","unstructured":"Denk D, Petrocelli V, Conche C, Drachsler M, Ziegler PK, Braun A et al. Expansion of T memory stem cells with superior anti-tumor immunity by urolithin A-induced mitophagy. Immunity. 2022; 55(11).","DOI":"10.1016\/j.immuni.2022.09.014"},{"issue":"18","key":"679_CR188","doi-asserted-by":"publisher","first-page":"e2310065","DOI":"10.1002\/advs.202310065","volume":"11","author":"S Ma","year":"2024","unstructured":"Ma S, Wu Q, Wu W, Tian Y, Zhang J, Chen C, et al. Urolithin A hijacks ERK1\/2-ULK1 cascade to improve CD8\u2009+\u2009T cell fitness for antitumor immunity. Adv Sci (Weinh). 2024;11(18):e2310065.","journal-title":"Adv Sci (Weinh)"},{"key":"679_CR189","doi-asserted-by":"crossref","unstructured":"Dai Y, Liu Y, An L, Zhong F, Zhang X, Lou S. Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming. J Immunother Cancer. 2024; 12(11).","DOI":"10.1136\/jitc-2024-009949"},{"issue":"7","key":"679_CR190","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the Art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"1","key":"679_CR191","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trecan.2020.09.002","volume":"7","author":"M Ecsedi","year":"2021","unstructured":"Ecsedi M, McAfee MS, Chapuis AG. The anticancer potential of T cell Receptor-Engineered T cells. Trends Cancer. 2021;7(1):48\u201356.","journal-title":"Trends Cancer"},{"issue":"1","key":"679_CR192","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva A, Zajic S, Chang Y-F, Houseman EA, Zhong S, Kim J, et al. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun. 2022;13(1):5296.","journal-title":"Nat Commun"},{"issue":"25","key":"679_CR193","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.18632\/oncotarget.28132","volume":"12","author":"R Hsu","year":"2021","unstructured":"Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, et al. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021;12(25):2449\u201358.","journal-title":"Oncotarget"},{"issue":"22","key":"679_CR194","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, et al. Neoantigen T-Cell receptor gene therapy in pancreatic Cancer. N Engl J Med. 2022;386(22):2112\u20139.","journal-title":"N Engl J Med"},{"issue":"10435","key":"679_CR195","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay J-Y, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371.","journal-title":"Lancet"},{"issue":"8","key":"679_CR196","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4(8):101133.","journal-title":"Cell Rep Med"},{"issue":"4770","key":"679_CR197","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318\u201321.","journal-title":"Science"},{"issue":"25","key":"679_CR198","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"17","key":"679_CR199","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","volume":"29","author":"TJ Monberg","year":"2023","unstructured":"Monberg TJ, Borch TH, Svane IM, Donia M. TIL therapy: facts and hopes. Clin Cancer Res. 2023;29(17):3275\u201383.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"679_CR200","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"679_CR201","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","volume":"128","author":"K Brummel","year":"2023","unstructured":"Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128(3):451\u20138.","journal-title":"Br J Cancer"},{"key":"679_CR202","doi-asserted-by":"crossref","unstructured":"Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021; 9(5).","DOI":"10.1136\/jitc-2020-001743"},{"issue":"2","key":"679_CR203","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","volume":"75","author":"JG Crompton","year":"2015","unstructured":"Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, et al. Akt Inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75(2):296\u2013305.","journal-title":"Cancer Res"},{"issue":"1","key":"679_CR204","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13046-021-02184-2","volume":"40","author":"A Sharma","year":"2021","unstructured":"Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021;40(1):388.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"679_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1285987","volume":"13","author":"Y Meng","year":"2017","unstructured":"Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: from Preparation and testing to clinical application. Hum Vaccin Immunother. 2017;13(6):1\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"679_CR206","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","volume":"8","author":"X Gao","year":"2017","unstructured":"Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X, et al. Cytokine-Induced killer cells as Pharmacological tools for Cancer immunotherapy. Front Immunol. 2017;8:774.","journal-title":"Front Immunol"},{"issue":"5","key":"679_CR207","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00432-014-1864-3","volume":"141","author":"LC Schmeel","year":"2015","unstructured":"Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IGH. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015;141(5):839\u201349.","journal-title":"J Cancer Res Clin Oncol"},{"key":"679_CR208","doi-asserted-by":"publisher","first-page":"1389725","DOI":"10.3389\/fonc.2024.1389725","volume":"14","author":"T Liu","year":"2024","unstructured":"Liu T, Wang H, Kong Q, Wang H, Wei H, Sun P. Long-term, 13-year survival after immune cell therapy combined with chemotherapy for extensive-stage small-cell lung cancer: a case report. Front Oncol. 2024;14:1389725.","journal-title":"Front Oncol"},{"issue":"5","key":"679_CR209","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1078-0432.CCR-18-2360","volume":"25","author":"G Qiao","year":"2019","unstructured":"Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, et al. Autologous dendritic cell-Cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: A prospective study. Clin Cancer Res. 2019;25(5):1494\u2013504.","journal-title":"Clin Cancer Res"},{"key":"679_CR210","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.intimp.2018.06.012","volume":"61","author":"Z Xiao","year":"2018","unstructured":"Xiao Z, Wang C-Q, Zhou M-H, Li N-N, Liu S-Y, He Y-J, et al. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. Int Immunopharmacol. 2018;61:363\u201375.","journal-title":"Int Immunopharmacol"},{"key":"679_CR211","doi-asserted-by":"crossref","unstructured":"Vaseq R, Sharma A, Li Y, Schmidt-Wolf IGH. Revising the landscape of Cytokine-Induced killer cell therapy in lung cancer: focus on immune checkpoint inhibitors. Int J Mol Sci. 2023; 24(6).","DOI":"10.3390\/ijms24065626"},{"issue":"8","key":"679_CR212","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cllc.2022.07.009","volume":"23","author":"L Zhou","year":"2022","unstructured":"Zhou L, Xiong Y, Wang Y, Meng Y, Zhang W, Shen M, et al. A phase IB trial of autologous Cytokine-Induced killer cells in combination with sintilimab, monoclonal antibody against programmed cell Death-1, plus chemotherapy in patients with advanced Non-Small-Cell lung Cancer. Clin Lung Cancer. 2022;23(8):709\u201319.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"679_CR213","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41419-018-0404-5","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen D, Sha H, Hu T, Dong S, Zhang J, Liu S, et al. Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer. Cell Death Dis. 2018;9(3):366.","journal-title":"Cell Death Dis"},{"issue":"8","key":"679_CR214","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022;21(8):559\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"679_CR215","doi-asserted-by":"publisher","first-page":"1192907","DOI":"10.3389\/fimmu.2023.1192907","volume":"14","author":"E Shin","year":"2023","unstructured":"Shin E, Bak SH, Park T, Kim JW, Yoon S-R, Jung H, et al. Understanding NK cell biology for Harnessing NK cell therapies: targeting cancer and beyond. Front Immunol. 2023;14:1192907.","journal-title":"Front Immunol"},{"issue":"1","key":"679_CR216","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi Y, Hao D, Qian H, Tao Z. Natural killer cell-based cancer immunotherapy: from basics to clinical trials. Exp Hematol Oncol. 2024;13(1):101.","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"679_CR217","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-20-0768","volume":"26","author":"S-C Lee","year":"2020","unstructured":"Lee S-C, Shimasaki N, Lim JSJ, Wong A, Yadav K, Yong WP, et al. Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Clin Cancer Res. 2020;26(17):4494\u2013502.","journal-title":"Clin Cancer Res"},{"key":"679_CR218","doi-asserted-by":"publisher","first-page":"1074906","DOI":"10.3389\/fimmu.2022.1074906","volume":"13","author":"L Jia","year":"2022","unstructured":"Jia L, Chen N, Chen X, Niu C, Liu Z, Ma K, et al. Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy. Front Immunol. 2022;13:1074906.","journal-title":"Front Immunol"},{"issue":"4","key":"679_CR219","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12026-017-8927-x","volume":"65","author":"M Lin","year":"2017","unstructured":"Lin M, Liang S-Z, Wang X-H, Liang Y-Q, Zhang M-J, Niu L-Z, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65(4):880\u20137.","journal-title":"Immunol Res"},{"issue":"12","key":"679_CR220","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24(12):1994\u20132007.","journal-title":"Nat Immunol"},{"issue":"1","key":"679_CR221","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","volume":"16","author":"R Huang","year":"2023","unstructured":"Huang R, Wen Q, Zhang X. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol. 2023;16(1):35.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"679_CR222","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","volume":"112","author":"M Liu","year":"2022","unstructured":"Liu M, Huang W, Guo Y, Zhou Y, Zhi C, Chen J, et al. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukoc Biol. 2022;112(4):901\u201311.","journal-title":"J Leukoc Biol"},{"key":"679_CR223","doi-asserted-by":"publisher","first-page":"106656","DOI":"10.1016\/j.phrs.2023.106656","volume":"188","author":"Y Peng","year":"2023","unstructured":"Peng Y, Zhang W, Chen Y, Zhang L, Shen H, Wang Z, et al. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharmacol Res. 2023;188:106656.","journal-title":"Pharmacol Res"},{"issue":"1","key":"679_CR224","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12885-023-11806-1","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang C, He M, Xing W, Hou R, Zhang H. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer. 2024;24(1):119.","journal-title":"BMC Cancer"},{"issue":"4","key":"679_CR225","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nri2528","volume":"9","author":"JW Pollard","year":"2009","unstructured":"Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259\u201370.","journal-title":"Nat Rev Immunol"},{"key":"679_CR226","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-017-0083-4","volume":"6","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhang X. Pivotal regulators of tissue homeostasis and cancer: macrophages. Exp Hematol Oncol. 2017;6:23.","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"679_CR227","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s13402-024-00987-x","volume":"47","author":"C Huang","year":"2024","unstructured":"Huang C, Wang X, Wang L, Liu Y, Xia Z, Wang X, et al. Targeting tumor associated macrophages (TAMs) reprograms tumor immune microenvironment to promote solid tumor immunotherapy. Cell Oncol (Dordr). 2024;47(5):2011\u20134.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"679_CR228","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"679_CR229","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond). 2024;44(11):1231\u201360.","journal-title":"Cancer Commun (Lond)"},{"issue":"18","key":"679_CR230","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369.","journal-title":"Cancer Res"},{"key":"679_CR231","doi-asserted-by":"publisher","first-page":"120350","DOI":"10.1016\/j.ijpharm.2021.120350","volume":"598","author":"H Zhang","year":"2021","unstructured":"Zhang H, Almuqbil RM, Alhudaithi SS, Sunbul FS, da Rocha SRP. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model. Int J Pharm. 2021;598:120350.","journal-title":"Int J Pharm"},{"issue":"1","key":"679_CR232","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s40425-019-0812-9","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, et al. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. J Immunother Cancer. 2019;7(1):346.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"679_CR233","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"679_CR234","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12(1):86.","journal-title":"Biomark Res"},{"issue":"1","key":"679_CR235","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11(1):103.","journal-title":"Biomark Res"},{"issue":"1","key":"679_CR236","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-025-00608-9","volume":"14","author":"J Guoyun","year":"2025","unstructured":"Guoyun J, Yuefeng Q, Zhenglan H, Zuowei Y, Hongyan Z, Ying Y, et al. CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells. Exp Hematol Oncol. 2025;14(1):14.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"679_CR237","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25(1):102\u201316.","journal-title":"Nat Immunol"},{"key":"679_CR238","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"issue":"12","key":"679_CR239","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.it.2022.10.002","volume":"43","author":"LM Sly","year":"2022","unstructured":"Sly LM, McKay DM. Macrophage immunotherapy: overcoming impediments to realize promise. Trends Immunol. 2022;43(12):959\u201368.","journal-title":"Trends Immunol"},{"key":"679_CR240","doi-asserted-by":"crossref","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020; 20(1).","DOI":"10.1038\/s41577-019-0210-z"},{"issue":"4","key":"679_CR241","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12026-017-8931-1","volume":"65","author":"J Constantino","year":"2017","unstructured":"Constantino J, Gomes C, Falc\u00e3o A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65(4):798\u2013810.","journal-title":"Immunol Res"},{"issue":"1","key":"679_CR242","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"679_CR243","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.maturitas.2011.04.012","volume":"69","author":"E Thara","year":"2011","unstructured":"Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011;69(4):296\u2013303.","journal-title":"Maturitas"},{"issue":"1","key":"679_CR244","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6(1):26.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"679_CR245","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13256-024-04363-z","volume":"18","author":"T Kosumi","year":"2024","unstructured":"Kosumi T, Kobayashi M, Shimodaira S, Sugiyama H, Koido S. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report. J Med Case Rep. 2024;18(1):88.","journal-title":"J Med Case Rep"},{"issue":"1","key":"679_CR246","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540.","journal-title":"Nat Commun"},{"issue":"1","key":"679_CR247","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z-F Lim","year":"2019","unstructured":"Lim Z-F, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"679_CR248","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/1759-7714.13731","volume":"12","author":"Y Han","year":"2021","unstructured":"Han Y, Mu D, Liu T, Zhang H, Zhang J, Li S, et al. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. Thorac Cancer. 2021;12(2):145\u201352.","journal-title":"Thorac Cancer"},{"issue":"20","key":"679_CR249","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"679_CR250","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","volume":"40","author":"C Xie","year":"2021","unstructured":"Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer. J Exp Clin Cancer Res. 2021;40(1):266.","journal-title":"J Exp Clin Cancer Res"},{"key":"679_CR251","doi-asserted-by":"crossref","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023; 11(3).","DOI":"10.1136\/jitc-2022-005583"},{"issue":"10","key":"679_CR252","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met \u00d6, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450\u20138.","journal-title":"Lancet Oncol"},{"issue":"11","key":"679_CR253","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353.","journal-title":"Nat Med"},{"issue":"6","key":"679_CR254","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nri.2016.42","volume":"16","author":"MG Rooks","year":"2016","unstructured":"Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"7741","key":"679_CR255","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(7741):600\u20135.","journal-title":"Nature"},{"key":"679_CR256","doi-asserted-by":"crossref","unstructured":"Bachem A, Makhlouf C, Binger KJ, de Souza DP, Tull D, Hochheiser K et al. Microbiota-Derived Short-Chain fatty acids promote the memory potential of Antigen-Activated CD8\u2009+\u2009T cells. Immunity. 2019; 51(2).","DOI":"10.1016\/j.immuni.2019.06.002"},{"issue":"D1","key":"679_CR257","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53(D1):D1670\u20136.","journal-title":"Nucleic Acids Res"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00679-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:30:32Z","timestamp":1751959832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":257,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00679-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}